Browsed by
Tag: covid19

Key Summary of CapitaLand Mall Trust’s AGM on 26 June 2020 (Guest Post)

Key Summary of CapitaLand Mall Trust’s AGM on 26 June 2020 (Guest Post)

Retail REIT CapitaLand Mall Trust (SGX:C38U) held its AGM for FY2019 on Friday, 26 June 2020, at 4pm. Due to the ongoing Covid-19 outbreak, along with the safe distancing measures implemented by the Singapore government, the meeting was held online.

image-55-min

This post was originally posted here. The writer, Lim Jun Yuan is a veteran community member and blogger on InvestingNote, with username known as ljunyuan and has 1241  followers.

I have attended the meeting as a unitholder and in this post, you will find a summary of the most important pointers of CEO Tony Tan Tee Hieong’s presentation to take note of (which I have compiled for the benefit of unitholders who did not manage to attend the meeting):

Key Highlights of FY2019:

  • Distributable income have grew steadily over the years, and in the latest financial year under review (i.e. FY2019), it saw a 7.5% year-on-year (y-o-y) improvement to S$441.6m. Correspondingly, the REIT saw its distribution per unit increase by 4.1% compared to the previous financial year to 11.97 cents/unit
  • Annual shopper traffic saw a 1.4% y-o-y improvement due to stronger performance from suburban malls, while its tenants’ sales per square foot dipped by 1.4% in the same time period due to lower sales from the REIT’s home furnishing and electrical and electronics tenants
  • In terms of the REIT’s overall portfolio occupancy rate, at 99.3% as at 31 December 2019, Mr Tan highlighted that it is above Singapore’s average portfolio occupancy for retail malls (which is 92.9% for suburban malls, and 92.0% for Orchard Road malls)
  • With regard to CapitaLand Mall Trust’s debt maturity profile as at 31 December 2019, Mr Tan updated while there is S$310.2m of debt that will be expiring in the year 2020, there are bank facilities in place to refinance the entire amount. On top of that, Mr Tan also added that there are no foreign exchange risks as all the REIT’s debts are swapped to the Singapore dollar

Read More Read More

HYPHENS PHARMA: IS THIS PHARMA COMPANY UNDERVALUED? (Guest Post)

HYPHENS PHARMA: IS THIS PHARMA COMPANY UNDERVALUED? (Guest Post)

The company was founded in 1998 and was listed on the Singapore Exchange’s Catalist board back in 2018. Hyphens’ share price performance was rather lackluster since its listing, hovering significantly below its IPO price of S$0.26 and hit a low of S$0.18 during the recent March COVID-19 pandemic driven sell-down.

Preview Image

Hyphens Pharma revs up digital push amid Covid-19, Companies ...

This post was originally posted here. The writer, Royston Tan is a veteran community member and blogger on InvestingNote, with username known as Royston_Tan.

However, following a strong set of 1Q20 results, the company’s share price subsequently rebounded to hit an all-time high of S$0.39 in June 2020. Is there potentially more share price upside for the company? Let’s take a closer look.

Hyphens Pharma (Hyphens) is Singapore’s leading specialty pharmaceutical and consumer healthcare group. The company operates in three business segments:

Specialty Pharma Principals which is the largest contributor of both revenue and earnings to the Group. The company boasts more than 30 products in its portfolio and this figure is consistently increasing.

Proprietary Brands currently comprise of dermocosmetic products marketed under Ceradan® and TDF® brands as well as health supplement products marketed under their Ocean Health® brand. While this segment generates the lowest profitability among the three segments due to heavy investments in brand building, it has the highest revenue growth potential as well as earnings longevity.

Medical Hypermart and Digital is a B2B model where the company engages in the wholesale of pharmaceuticals and medical supplies in Singapore through Pan-Malayan. This segment is the second-largest revenue and earnings contributor to the Group but we note the potential lumpiness in revenue/earnings from one-off large tenders.

STEADY FINANCIAL PERFORMANCES OVER THE PAST 3 YEARS
INCOME STATEMENT

The company’s past 3-years financials painted a picture of earnings stability but not one that is truly exciting. While its reported net profit declined from S$6.1m in 2017 to S$5.4m in 2018, this was due to one-off IPO expenses amounting to c.S$0.9m. Its adjusted net profit was S$6.3m in 2018, representing a 3.6% YoY growth. In 2019, earnings grew by a similar 3.5%, a rate likely deemed too low by the market to justify a share price re-rating.

However, despite widespread business standstill in 1Q20 due to COVID-19, the company reported a strong set of 1Q20 financial results with Group revenue growing by 16.4% YoY, spearheaded by its proprietary brand segment. Coupled with slower growth in expenses, Hyphens’ 1Q20 operating margins improved by 1.6ppt and consequently grew its net profit by 48.6% YoY to hit S$2.1m.

Read More Read More